Monthly Update: Biologicals & Immunologicals: New drugs for the treatment of HIV infection

References

• CLERICI M, SHEARER GM: The Th1-Th2 hypothesis of HIV infection: new insights. Immunology Today (1994) 15(12):575–581.
   PubMedGoogle Scholar
• DALGLEISH AG: Autoiramune mechanisms of depletion of C04 cells in HIV infection. Br.J. Haem. (1995). In press.
   Google Scholar
• DALGLEISH AG: The immune response to HIV: potential for brununotherapy? Immunology Today (1995) 16(7):356–359.
   PubMedGoogle Scholar
• HERMANDEZTANDO R, ROOK GA: The role of TNFIx in T-cell mediated inflammation depends on the Thl/Th2 cytokine balance. Immunology (1994) 82(4):591–595.
   PubMed Web of Science ®Google Scholar
• LARDER BA, DAR13Y G, RICHMAN DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during pro-longed therapy. Science (1989) 243: 1731-1734.
   Google Scholar
• MONTANER JSG, SINGER J, SCHECHTER MR, RABOUD JM, TSOUKAS C, ET AL.: Clinical correlates of in vitro HIV-I resistance to zidovudine. Results of the multicenter Canadian AZT triaL AIDS (1993) 7:189–196.
   Google Scholar
• TUDOR-WILLIAMS G, ST CLAIR MH, MCKINNEY RE, MAHA M, WALTER E, SANTACROCE S, MINTZ M, O'DONNELL K, RUDOLL T, VAVRO CL, CONNOR EM, WILFERT CM: 112V-1 sensitivity to zidovudine and clinical outcome in chil-dren. Lancet (1994 339:15–19.
   Google Scholar
• ST CLAIR MH, HARTIGAN PM, ANDREWS JC, VAVRO CL,SIMBERKOFF MS, ET AL.: Zidovudine resistance, syncytium-inducing phenotype and HIV disease pro-gression in a case control study. J. AIDS (1993) 6:891–897.
   Google Scholar
• ROOKE R, PARNIAK MA, TREMBLAY M, SOUDEYNS H, LI X, ET AL.: Biological comparison of wild-type and zi-dovudine-resistant isolates of human immunodefi-ciency virus type 1 from the same subjects: susceptibility and resistance to other drugs. Antimicrob. Agents Chemother. (1991) 35:988–991.
   Google Scholar
• UN P-F, SAMANTA H, ROSE RE, PATRICK AK, ET AL.:Genotypic and phenotypic analysis of human immu-nodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J. Infect. Dis. (1994) 170:1157–1164.
   Google Scholar
• FITZGIBBON JE, HOWELL IIM, HABERZETrL CA, SPERBERSJ, GOCKE DJ, ET AL.: Human immunodeficiency virus type 1 pot gene mutations which cause decreased sus-ceptibility to 2',3'-dideoxy cytidine. Antimicrob. Agents Chemother. (1992) 36:153–157.
   Google Scholar
• ST CLAIR MIL MARTIN JL, TUDOR-WILLIAMS G, BACH MC,VAVRO, ET AL.: Resistance to DDI and sensitivity to AZT Induced by a mutation in WV-1 reverse transcriptase. Science (1991) 253:1557–1559.
   Google Scholar
• SHAFER RW, KOZAL MJ, WINTERS MA, IVERSEN AKN, KATZENSTEIN DA, RAGNI MV, MEYERE WA III, GUPTA P, RASHEED S, COOMBS R, KATZMAN M, FISCUS S, MERIGAN TC: Combination therapy with zidovudine and didanos-ine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. (1994) 169:722–729.
   PubMed Web of Science ®Google Scholar
• FITZGIBBON JE, FARNHAM AE, SPERBER SJ, KIM H, DUBINDT: Human immunodeficiency virus type 1 poi gene mutation in an AIDS patient treated with multiple antiretroviral drugs. J. Virol. (1993) 67:7271–7275.
   PubMed Web of Science ®Google Scholar
• LARDER BA: The influence of combination therapy onHIV-1 viral load and drug resistance. AIDS (1994) 8:S4.
   Google Scholar
• KOHLSTAEDT LA, WANG J, FRIEDMAN JM, RICE PA, STEITZTA: Crystal structure at 3.5A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (1992) 256:1783–1790.
   Google Scholar
• LARDER BA, KELLAM P, KEMP SD: Convergent combina-tion therapy can select variable multidrug resistant HIV-1 in vitro. Nature (1993) 365:451–453.
   PubMed Web of Science ®Google Scholar
• ROSE B, GREYTOKJ, BECHTOLD C: Combination therapywith two proteinase inhibitors as an approach to an-tiviral therapy. Third International Workshop on HIV drug resistance. Kauai, August 1994.
   Google Scholar
• EMINI EA, DETSCH P, SCHLEIF WA, GONDRA JH: Clinicaldevelopment of HIV resistance to the viral protease Inhibitor L735, 524. AIDS (1994) 8:S10.
   Google Scholar
• GAZZARD BG, MOYLE GJ: Individualisation of HIV ther-apy: the clinician's perspective. BJCP (1995) 49(3):145–147.
   Web of Science ®Google Scholar
• PANTALEO G, MENZO S, VACCAREZZA M ET AL.: StudiesIn subjects with long-term non-progressive human immunodeficiency virus infection. New Engl. J. Med. (1995) 332:209–216.
   Google Scholar
• O'BRIEN WA, HARRIGAN PM, MCCREADY B, HAMILTONJD: Plasma HIV RNA andrI2 microglobulin as surrogate markers. Xth International Conference on AIDS. Yokohama, 1994.
   Google Scholar
• YERLY 5, KAISER L, MERMILLOD B, ET AL.: Response of HIV RNA to didanosine as a predictive marker of sur-vivaL AIDS (1995) 9:159–163.
   Google Scholar
• BOUCHER CAB: Individualisation of HIV therapy: the virologist's perspective. 2nd International Congress on Drug Therapy in HIV infection. Glasgow, 1994.
   Google Scholar
• KOOT M, SCHELLEKENS, P MULDER J, ET AL.: Viral phe-notype and T-cell reactivity in human imnnmodell-ciency virus type 1-infected asymptomatic men treated with zidovudine. J. Infect. Dis. (1993) 168:733–766.
   Google Scholar
• ELLENBERG SE: Surrogate end points in clinical trials. BMJ (1991) 302:63–64.
   PubMed Web of Science ®Google Scholar
• ELLENBERG SS: Surrogate endpoints. Br. J. Cancer (1993) 68:457–459.
   PubMed Web of Science ®Google Scholar
• LAGAKOS SW: Surrogate markers in AIDS clinical trials: conceptual basis, validation and uncertainties. Clin. Infect. Diseases (1993) 16(1):S22–S25.
   PubMedGoogle Scholar
• KOVACS JA, BASELLER M, DEWAR RJ, VOGEL S, DAVEY RT, FALLOON J, POLIS MA, WALKER RE, STEVENS R, SALZMAN NP, METCALF JA, MASUR H, LANE HC: Increases in CD4 T-lymphocytes with intermittent courses of IL-2 in patients with human immunodeficiency virus infec-tion. New Engl. J. Med. (1995) 332(9):567–575.
   PubMed Web of Science ®Google Scholar
• SCHEY S, AITKEN C, DALGLEISH AG: Virus infections in the inununocompromised host. In: Infection and Hae-matology. Jenkins GC, Williams JD (Eds.). Butterworth He-ineman, Oxford (1994):164–173.
   Google Scholar
• FERDMAN EM, CHURCH JA: Immunological and virologi-cal effects of glucocorticolds on HIV in children. Fed. Inf. Dis. Journal (1994) 13(3):212–216.
   PubMedGoogle Scholar
• GAGNON S, BOOTA AM, FISCHL MA, BAIER H, KIRKSEY OW, LA VOIE L: Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the AIDS patient. A double-blind, placebo-controlled trial. New Engl. J. Med. (1990) 323(21):1444–1450.
   PubMed Web of Science ®Google Scholar
• LIM SG, LEE CA, KERNOFF PB: Treatment of HIV associ-ated thrombocytopenia. Clin. Lab. Haem. (1990) 12(3):237–245.
   PubMedGoogle Scholar
• ALLEN BR: Use of cyclosporin for psoriasis in HIV positive patient. Lancet (1992) 339(8801):1110.
   Google Scholar
• DRUMMER JS, ERB S, BREINIG MK, ET AL.: Infection withHIV in the Pittsburgh transplant population. Transplan-tation (1989) 47(1):134–140.
   Google Scholar
• SCHWARTZ A, OFFERMANN G, KELLO F, ET AL.: The effect of cyclosporin on the progression of 1HV-1 transmitted by transplantation. Transplantation (1993) 55(1):85–103.
   Google Scholar
• GUNZLER V: Thalidomide in HIV patients. Drug Safety (1992) 7(2):116–134.
   PubMed Web of Science ®Google Scholar
• MAKOONKAWKEYOON S, LIMSON-POBRE RN. MOREIRAAL, SCHAUF V, KAPLAN G: Thalidomide inhibits the replication of HIV-1. PNAS (1993) 90(13):5974–5978.
   PubMed Web of Science ®Google Scholar
• ANDRIEU J-M, LU W, LEVY R: Sustained increases in CD4cell counts in asymptomatic HIV-1 seropositive patients treated with prednisolone for 1 year. J. Infect. Dis. (1995) 171:523–530.
   PubMed Web of Science ®Google Scholar
• WEBER J: Cyclosporhi A and HIV. Nature (1995). Corre-spondence.
   Google Scholar
• ANDRIEU J-M: Personal communication.
   Google Scholar
• DEBUZE BJ: Pentoxyphylline for treatment of HIV. din.Inf Dis. (1994) 18(3):285–287.
   Google Scholar
• CHEHIMI J, TRINDRIERI G: I1-12: abridge between innateresistance and adaphnic immunity in HIV. J. din. Im-munol. (1994) 14(3):149–161.
   Google Scholar
• WITSCHI A, JUNKER E, SCHRANZ C, SPECK RE, LAUTER-BURG BH: Supplementation of N-acetylcysteine fails to Increase glutathione in lymphocytes and plasma of patients with AIDS. AIDS Res. & Human Retro. (1995) 11(1):141.
   PubMed Web of Science ®Google Scholar
• NEWMAN GW, KATARZYNA M, SABLINSKA B, GUARNAC-CIA JR, REMOLD HG, SILBERSTEIN DS: Opposing regula-tory effects of thioredoxin and eosinophil cytotoxicity-enhancing factor on the development of HIV-1.j Exp. Med. (1994) 180:359–363.
   PubMed Web of Science ®Google Scholar
• YU M, POESCHLA E, WONG-STAAL F: Progress towards gene therapy for HIV infection. Gene Therapy (1994) 1(1):13–26.
   PubMed Web of Science ®Google Scholar